Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
$5.25
-$0.11(-3.01%)
At close: 4:00 PM EST
$5.25
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.88 - $6.72
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$311.38M
Enterprise Value-$20.44M
Total Cash (Recent Filing)$163.66M
Total Debt (Recent Filing)$17.44M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding68,737,220
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-1.44
Enterprise Value/Market Cap-0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.43
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$10.00Price Target Upside90.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe FREEDOM2 multiple ascending dose trial is progressing, with data expected to be promising based on the robust 54% mean splicing correction achieved in the single dose FREEDOM trial.
Market PositionPepGen stands out as the hidden gem in a space validated by recent M&A, with a stronger balance sheet and extended runway.
Patent And ExclusivityPepGen’s newly issued U.S. patent secures long-term exclusivity for PGN-EDODM1, reinforcing the durability of its DM1 franchise.
Bears Say
Development PacePEPG is behind competitors in development, and it remains unclear if an accelerated path will be open.
Safety And RiskThe safety profile still needs de-risking due to potential readthrough from the discontinued DMD program, where asymptomatic cases of hypomagnesemia were observed.
Safety Profile ConcernsClarity on the safety profile of PEPG’s proprietary EDO platform is still needed, given the readthrough risk from the discontinued DMD program.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $6.72 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $311.38M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 105 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Nov 12, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.565 by $0.045.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.37.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 68,737,220 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.565. Following the earnings report the stock price went up 10.323%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
PepGen Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (90.48% Upside)
$10.00 (90.48% Upside)
Hedge Fund Trend
Increased
By 13.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-62.25%
Trailing 12-Months
Asset Growth
-47.16%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$10.00
▲(90.48% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
I-MAB
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---